Key Takeaways United Therapeutics surged 33% after positive results from the TETON-2 Tyvaso study in IPF.Tyvaso showed superiority over placebo in lung function after 52 weeks with consistent safety.UTHR aims to expedite review by meeting the FDA this year ahead of TETON-1 results in 2026.Shares of United Therapeutics (UTHR) surged 33% on Tuesday after it announced positive top-line results from the late-stage TETON-2 study evaluating the nebulized version of Tyvaso (treprostinil) in adult patients with idi ...

Liquidia Corporation LQDA reported on Tuesday a second-quarter loss of 49 cents, missing the consensus of a loss of 43 cents.See the LGDA stock price story here.Sales reached $8.84 million compared to the consensus of $3.86 million.The net Product revenue was $6.5 million for the three months ending June 30, 2025. After receiving full FDA approval for Yutrepia on May 23, 2025, the company began shipping Yutrepia to customers in the U.S. in June 2025.Liquidia did not recognize any product revenue during the ...